Navigation Links
Conseco Declines Partnership's Request for Board Seats; Review of Strategic Alternatives Underway
Date:3/17/2008

CARMEL, Ind., March 17 /PRNewswire-FirstCall/ -- Conseco, Inc. (NYSE: CNO) today announced that it is declining a request from Steel Partners II, L.P. to nominate two of its representatives to Conseco's board of directors. Conseco also announced that it has been reviewing strategic alternatives and has engaged the investment banking firm of Morgan Stanley as its strategic advisor.

Conseco CEO Jim Prieur said, "We share with Steel Partners, as well as our other shareholders, a common interest in taking actions that will increase the value of the company for shareholders. In that regard, we have been working with a major investment bank for several months regarding strategic alternatives and plans to maximize shareholder value for Conseco. We believe, and hope Steel Partners would concur, that we already are exploring courses of action suggested by them."

Steel Partners President Jack L. Howard asked Conseco on March 14 to nominate himself and Chief Executive Warren G. Lichtenstein to the board of directors. Steel Partners said their intention was to work with the company to engage an investment bank to assist Conseco in exploring alternatives to maximize shareholder value.

Conseco, Inc.'s insurance companies help protect working American families and seniors from financial adversity: Medicare supplement, long-term care, cancer, heart/stroke and accident policies protect people against major unplanned expenses; annuities and life insurance products help people plan for their financial futures. For more information, visit Conseco's web site at http://www.conseco.com.


'/>"/>
SOURCE Conseco, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Conseco Files to Formally Extend Due Date for Annual Report on Form 10-K to March 17 and Reschedules Earnings Release and Investor Call
2. Hacker Joins Conseco as Senior Vice President and Treasurer
3. Tongson Joins Conseco as Senior Vice President, Corporate Actuarial
4. Conseco to Implement Systems and Operational Solution From Long Term Care Group
5. Conseco Reports Third Quarter Results
6. Conseco Sets Earnings Release Date
7. Conseco Completes Divestiture of Old Block of Fixed and Equity-Indexed Annuities
8. Barta joins Conseco as Senior Vice President, Financial Planning & Analysis; Barra named Senior Vice President, Internal Audit; Clarke to head Investor Relations
9. Conseco to Host Follow-Up Long-Term Care Conference Call
10. Pilot error declines as factor in airline mishaps
11. CDC Reports that Adult Smoking Declines Have Stalled; Elected Officials Should Step up Fight Against Tobacco
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6When palm trees gave way to spruce trees 8890 1When palm trees gave way to spruce trees 8890 2House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 1House Subcommittee Markup Leaves Global Fund to Fight AIDS TB and Malaria in Crisis 49310 2Mayo Clinic Plans Facility at Mall of America 49306 1Mayo Clinic Plans Facility at Mall of America 49306 2Mayo Clinic Plans Facility at Mall of America 49306 3